ABBV vs INTC: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Intel Corp. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Intel Corp. · Technology
$127.39
-8.4% upside to fair value
Low Conviction
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(-1.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
INTC |
| Current Price |
$261.70 |
$127.39 |
| Fair Value Estimate |
$259.04 |
$116.75 |
| Upside to Fair Value |
-1.0%
|
-8.4%
|
| Market Cap |
$462.4B |
$642.6B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
185.2x
|
| Price / Sales |
7.2x
|
11.3x
|
| Price / FCF |
23.6x
|
229.7x
|
| Revenue Growth YoY |
+10.2%
|
+25.4%
|
| Gross Margin |
71.5%
|
38.9%
|
| Operating Margin |
29.3%
|
0.1%
|
| Return on Equity |
-136.5%
|
-10.8%
|
| Dividend Yield |
2.61% |
0% |
| FCF Yield |
4.25%
|
0.44%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Intel designs and manufactures CPUs, GPUs, networking silicon, and edge and data-center products across its Client Computing, Data Center and AI, and Intel Foundry segments, employing roughly 85,100 people under CEO Lip-Bu Tan. The business quality is currently low: TTM gross margin is 38.9%, TTM operating margin is 0.1%, TTM net margin is -19.8%, and ROE is -10.8%, so the company is not earning …
Accumulation Zones
| Metric |
ABBV |
INTC |
| Zone Low |
$194.28 |
$87.56 |
| Zone High |
$220.18 |
$99.24 |
| In Buy Zone? |
No
|
No
|